|
Alomone Labs
lpar6 ![]() Lpar6, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Anti-LPAR6+(P2RY5)+(extracellular)+Antibody/pm40001482-69-29-32 Average 93 stars, based on 1 article reviews
lpar6 - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Croda International Plc
1 stearoyl 2 hydroxy sn glycero 3 phosphate ![]() 1 Stearoyl 2 Hydroxy Sn Glycero 3 Phosphate, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/16%3A0+LPA/pmc03418163-153-14-26 Average 94 stars, based on 1 article reviews
1 stearoyl 2 hydroxy sn glycero 3 phosphate - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
OriGene
ta310972 antiapo a rabbit monoclonal antibody ![]() Ta310972 Antiapo A Rabbit Monoclonal Antibody, supplied by OriGene, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Lipoprotein+a+(LPA)+Rabbit+Monoclonal+Antibody/pmc09018215__hcg___15___e003489___s001-62-9-14 Average 90 stars, based on 1 article reviews
ta310972 antiapo a rabbit monoclonal antibody - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedChemExpress
oleoyl lpa ![]() Oleoyl Lpa, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/1-Oleoyl+lysophosphatidic+acid/pmc05207162-324-31-38 Average 93 stars, based on 1 article reviews
oleoyl lpa - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Alomone Labs
anti lpa1 ![]() Anti Lpa1, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Anti-LPAR1+(EDG2)+(extracellular)+Antibody/pmc09120792-46-7-13 Average 94 stars, based on 1 article reviews
anti lpa1 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Alomone Labs
anti lpa3 alr 033 ![]() Anti Lpa3 Alr 033, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Anti-LPAR3+(EDG7)+(extracellular)+Antibody/pm27605627-94-60-63 Average 90 stars, based on 1 article reviews
anti lpa3 alr 033 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Proteintech
lpar3 proteintech 19509 1 ap ![]() Lpar3 Proteintech 19509 1 Ap, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/EDG7-Specific+Antibody/ppr0694844-112-34-35 Average 93 stars, based on 1 article reviews
lpar3 proteintech 19509 1 ap - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Croda International Plc
lpa ![]() Lpa, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/C18%3A1+LPA/pmc06443858-24-2-6 Average 94 stars, based on 1 article reviews
lpa - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Cusabio
human lpa elisa kits ![]() Human Lpa Elisa Kits, supplied by Cusabio, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Human+lysophosphatidic+acid+(LPA)+Elisa+kit/pm29927323-89-23-33 Average 92 stars, based on 1 article reviews
human lpa elisa kits - by Bioz Stars,
2026-11
92/100 stars
|
Buy from Supplier |
|
Proteintech
lpa1 antibody ![]() Lpa1 Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/EDG2+Antibody/pmc05350330-36-0-5 Average 93 stars, based on 1 article reviews
lpa1 antibody - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
|
Croda International Plc
lysophosphatidic acid 857228 ![]() Lysophosphatidic Acid 857228, supplied by Croda International Plc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/C18+LPA/pmc06195446-530-20-31 Average 90 stars, based on 1 article reviews
lysophosphatidic acid 857228 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
TargetMol
lp a ![]() Lp A, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/lpa/Anti-Apolipoprotein+A+Antibody/10__1093_slash_ehjopen_slash_oeaf068-127-9-19 Average 93 stars, based on 1 article reviews
lp a - by Bioz Stars,
2026-11
93/100 stars
|
Buy from Supplier |
Image Search Results
Journal: Biomolecules
Article Title: Gintonin Binds to Reduced LPA4 Receptor Subtype in Human Cortical Neurons in Alzheimer's Disease Brains.
doi: 10.3390/biom15020179
Figure Lengend Snippet: Figure 2. Co-localization of the gintonin (GT)-binding site with the LPA4 receptor subtype and a selective reduction in LPA4 receptor subtype expression levels in patients with AD. (A) Representative confocal images of the LPA receptor subtypes (LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, and LPAR6; green) and GT (red) in the cortices of the HCs and patients with AD. Scale bar = 200 µm. The insert images focus on the co-localization between gintonin (GT) and the LAP receptor subtypes. Scale bar = 100 µm. (B) Quantitative analysis of the co-localization between the GT and LPA receptor subtypes. (C–F) Western blot analysis of the LPA receptor subtypes in brain tissue from the HCs and patients with AD. The results indicate a significant decrease in LPAR4 expression in patients with AD, whereas no significant differences were observed for the other LPA receptor subtypes. Statistical significance was determined using a t-test. Data are presented as mean ± SEM. * p < 0.05, ** p < 0.01. Original Western blot images can be found in Figure S1.
Article Snippet: The primary antibodies used were LPAR1 (1:2000, ALR031, Alomone Labs), LPAR2 (1:2000, ALR-032, Alomone Labs), LPAR3 (1:2000, ab23692, Abcam), LPAR4 (1:2000, ALR-034, Alomone Labs), LPAR5 (1:2000, ALR-035, Alomone Labs),
Techniques: Binding Assay, Expressing, Confocal, Analysis, Western Blot, Tissue
Journal: Mediators of Inflammation
Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin
doi: 10.1155/2017/6893560
Figure Lengend Snippet: LPA1 is required for AM966-induced phosphorylation of VE-cadherin. (a) HLMVECs (~70% confluent) were transfected with LPA1 siRNA (siLPA1) or control (sicont) for 72 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin, total VE-cadherin, and LPA1 antibodies. (b) Analysis of P-VE-cadherin by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) HLMVECs (~70% confluent) were transfected with minigenes encoding G α 12 or G α 13 peptide for 24 h, and then cells were treated with AM966 (1.0 μ M) for 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) HLMVECs (~70% confluent) transfected with LPA1 siRNA (siLPA1) or control (sicont) were plated on gold microelectrodes and then cells were treated with AM966 (1.0 μ M) or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.
Article Snippet:
Techniques: Phospho-proteomics, Transfection, Control, Software
Journal: Mediators of Inflammation
Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin
doi: 10.1155/2017/6893560
Figure Lengend Snippet: AM966-induced phosphorylation of VE-cadherin is not FAK-dependent. (a) HLMVECs (~70% confluent) transfected with siLPA1 or sicont were treated with AM966 (1.0 μ M) or DMSO for 30 min. Cell lysates were immunoblotted with phosphospecific FAK (P-FAK), total FAK, and LPA1 antibodies. (b) Analysis of P-FAK by densitometry of the results in (a) was performed by Image J software ( n = 3), and statistical analysis was shown. (c) Confluent HLMVECs were pretreated with FAK kinase inhibitor (0 to 10.0 μ M) for 1 h, and then cells were treated with DMSO or AM966 (1.0 μ M) for an additional 30 min. Cell lysates were immunoblotted with P-VE-cadherin and total VE-cadherin antibodies. (d) Analysis of P-VE-cadherin by densitometry of the results in (c) was performed by Image J software ( n = 3), and statistical analysis was shown. Shown are representative blots from three independent experiments. (e) Confluent HLMVECs were plated on gold microelectrodes and pretreated with FAK inhibitor (1.0 or 5.0 μ M) for 1 h and then stimulated by 1.0 μ M AM966 or DMSO. The TEER tracing represents pooled data (±SEM) from 3 independent experiments. (f) The resistance in response to AM966 treatments during indicated time period (e) was quantified and statistical analysis was performed.
Article Snippet:
Techniques: Phospho-proteomics, Transfection, Software
Journal: Mediators of Inflammation
Article Title: AM966, an Antagonist of Lysophosphatidic Acid Receptor 1, Increases Lung Microvascular Endothelial Permeability through Activation of Rho Signaling Pathway and Phosphorylation of VE-Cadherin
doi: 10.1155/2017/6893560
Figure Lengend Snippet: AM966 reduces pulmonary microvascular cell barrier integrity through LPA1/G α 12/13-mediated phosphorylation of MLC and VE-cadherin. AM966 is ligated to LPA1 and triggers RhoA/Rho kinase pathway, thereby increasing MLC phosphorylation and cytoskeletal rearrangement. AM966 induces phosphorylation of VE-cadherin. Therefore, AM966 increases lung endothelial permeability.
Article Snippet:
Techniques: Phospho-proteomics, Permeability
Journal: European Heart Journal Open
Article Title: Fueling Stenosis: The integral role of PFKFB3-mediated glycolysis in Lp(a)-induced Valve Inflammation
doi: 10.1093/ehjopen/oeaf068
Figure Lengend Snippet: Figure 3. Lp(a) stimulation of VICs results in a PFKFB3-dependent increase in glycolysis. 2
Article Snippet: After 2 days, VICs were stimulated overnight with 100mg/dl Lp(
Techniques: